MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Avadel Pharmaceuticals plc DIO Ratio 2011-2026 | AVDL
Annual DIO Ratio Avadel Pharmaceuticals plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 366 | 2.24 K | - | - | - | 107 | 99.4 | 138 | 89.8 | 139 | 726 | 316 | 94.7 | 97.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.24 K | 89.8 | 401 |
Quarterly DIO Ratio Avadel Pharmaceuticals plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 315 | 333 | - | 218 | 413 | 669 | - | 2.62 K | - | - | - | - | - | - | - | - | - | - | - | - | 48.9 | 132 | - | 115 | 89.9 | 117 | - | 140 | 124 | 75.6 | - | 148 | 123 | 110 | - | 105 | 76.1 | 80.9 | - | 160 | 129 | 137 | - | 287 | 963 | 445 | - | 125 | 65.9 | 69.7 | - | 48.6 | 103 | 124 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.62 K | 48.6 | 272 |
DIO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
58.7 | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
48.9 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
459 | - | - | $ 754 M | USA |
 |
Cronos Group
CRON
|
221 | $ 2.69 | 1.32 % | $ 1.42 B |  Canada |
 |
Canopy Growth Corporation
CGC
|
167 | $ 1.25 | -3.02 % | $ 134 M | Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
133 | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
82.7 | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
71.9 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
460 | - | - | $ 50.1 M | USA |
 |
HEXO Corp.
HEXO
|
703 | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
149 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
100 | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
2.83 K | $ 1.74 | 0.29 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
85.9 | $ 4.17 | -1.07 % | $ 549 M | USA |
 |
Emergent BioSolutions
EBS
|
176 | $ 12.94 | -3.14 % | $ 663 M | USA |
 |
Evoke Pharma
EVOK
|
995 | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
158 | - | -23.39 % | $ 1.76 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
117 | $ 3.65 | -3.44 % | $ 4.53 M | USA |
 |
Evolus
EOLS
|
50.3 | $ 5.61 | -2.35 % | $ 348 M | USA |
 |
Harrow Health
HROW
|
80.1 | $ 47.21 | -7.51 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
168 | $ 1.29 | -4.79 % | $ 22.5 M |  China |
 |
Tilray
TLRY
|
170 | $ 9.15 | 0.26 % | $ 5.65 B | Canada |
 |
Jupiter Wellness
JUPW
|
59.7 | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
172 | $ 7.47 | -3.93 % | $ 2.73 B | Canada |
 |
Lannett Company
LCI
|
127 | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
239 | $ 4.78 | -1.04 % | $ 67.2 M | USA |
 |
Veru
VERU
|
179 | $ 2.35 | 1.73 % | $ 317 M | USA |
 |
Aurora Cannabis
ACB
|
1.35 K | $ 4.25 | -0.47 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
246 | $ 23.67 | -9.03 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
64.9 | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
143 | $ 14.99 | 1.94 % | $ 2.06 B | USA |
 |
ProPhase Labs
PRPH
|
30.1 | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
49.1 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
165 | $ 1.08 | -0.46 % | $ 4.66 M | USA |
 |
Radius Health
RDUS
|
204 | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
28.5 | $ 0.94 | -3.6 % | $ 21.9 M | USA |
 |
OptiNose
OPTN
|
370 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
347 | $ 9.12 | -2.04 % | $ 648 M | USA |
 |
PLx Pharma
PLXP
|
97.2 | - | -27.8 % | $ 2.56 M | USA |
 |
TherapeuticsMD
TXMD
|
1.04 K | $ 2.09 | 1.46 % | $ 21.8 M | USA |
 |
Viatris
VTRS
|
140 | $ 12.74 | 1.07 % | $ 15.4 B | USA |
 |
Zomedica Corp.
ZOM
|
183 | - | -0.21 % | $ 98 M | USA |